GlaxoSmithKline's (GSK) hopes of a return to growth for its embattled respiratory division in 2016 have been knocked back after the failure of a large-scale trial of new drug Breo/Relvar.

These are exceptionally strong results, and could put GSK in pole position in COPD – a welcome reversal of fortune after a string of underwhelming results from Breo (fluticasone furoate/vilanterol).

Key established drug Advair/Seretide sales rose 13%, while sales on Revlar/Breo Ellipta were up 5%. Ventolin sales rose 5%. In General Medicines, GSK expects sales to increase in a mid-single ...

Innoviva is entitled to receive royalties from GSK on sales of RELVAR ® /BREO ® ELLIPTA ® and ANORO ® ELLIPTA ®. Innoviva’s other innovative healthcare assets include infectious disease and ...

Meanwhile GSK's lead inhalers include Trelegy Ellipta, projected to bring $3.3bn in 2024 sales, followed by Relvar/Breo Ellipta and Seretide/Advair GlobalData is the patent company of Pharmaceutical ...

Meanwhile GSK's lead inhalers include Trelegy Ellipta, projected to bring $3.3bn in 2024 sales, followed by Relvar/Breo Ellipta and Seretide/Advair GlobalData is the patent company of ...